<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ETF Trends &#187; XBI</title>
	<atom:link href="http://www.etftrends.com/tag/xbi/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.etftrends.com</link>
	<description>Setting the Pace for Exchange Traded Funds</description>
	<lastBuildDate>Sat, 26 May 2012 10:00:50 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Biotech ETFs for an M&amp;A Boom</title>
		<link>http://www.etftrends.com/2012/05/biotech-etfs-for-an-ma-boom/</link>
		<comments>http://www.etftrends.com/2012/05/biotech-etfs-for-an-ma-boom/#comments</comments>
		<pubDate>Wed, 16 May 2012 16:30:33 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PJP]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=85589</guid>
		<description><![CDATA[Strong  prospects for new drug approvals, a favorable M&#38;A environment, and a  positive fundamental outlook have the biotechnology industry looking healthy,  according to S&#38;P Capital IQ. Investors who want exposure to the overall sector should consider exchange traded funds to help mitigate single-stock risks.
The biotech sector is known for volatility &#8212; big [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2012/05/biotech-etfs-for-an-ma-boom/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs Weather Market Storm</title>
		<link>http://www.etftrends.com/2012/05/biotech-etfs-weather-market-storm/</link>
		<comments>http://www.etftrends.com/2012/05/biotech-etfs-weather-market-storm/#comments</comments>
		<pubDate>Mon, 14 May 2012 14:20:53 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=85330</guid>
		<description><![CDATA[One sector that has held up very well amid weakness in the overall market is biotech. In fact, ETFs tracking the biotech stocks remain near all-time highs on successful drug trial tests and some investors positioning for deals in the sector.
The iShares Nasdaq Biotechnology (NasdaqGM: IBB) is up 21.2% year to date, more than doubling [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2012/05/biotech-etfs-weather-market-storm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Choosing the Right Biotech ETF Exposure</title>
		<link>http://www.etftrends.com/2012/04/choosing-the-right-biotech-etf-exposure/</link>
		<comments>http://www.etftrends.com/2012/04/choosing-the-right-biotech-etf-exposure/#comments</comments>
		<pubDate>Fri, 20 Apr 2012 19:09:26 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Asset Class ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[ETF 101]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[Large-Cap]]></category>
		<category><![CDATA[Mid-Cap]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Small-Cap]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=83289</guid>
		<description><![CDATA[Coming off the hopeful drug trial tests and lucrative takeover bids, the biotech sector and related exchange traded funds that follow the industry surged this week. However, some biotechnology ETFs are doing better than the others.
The large biotech firms are flush with cash and the overall sector is ripe with takeover bids on small up-and-comers [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2012/04/choosing-the-right-biotech-etf-exposure/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs Soar on Human Genome Bid, Gilead Drug Results</title>
		<link>http://www.etftrends.com/2012/04/biotech-etfs-soar-on-human-genome-bid-gilead-drug-results/</link>
		<comments>http://www.etftrends.com/2012/04/biotech-etfs-soar-on-human-genome-bid-gilead-drug-results/#comments</comments>
		<pubDate>Thu, 19 Apr 2012 14:55:47 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=83176</guid>
		<description><![CDATA[Biotech ETFs were the strongest market sector by far in early trading Thursday as portfolio holdings Human Genome Sciences (NasdaqGS: HGSI) and Gilead Sciences (NasdaqGS: GILD) soared on a takeover bid and encouraging drug results.
Human Genome shares rallied more than 100% following an unsolicited buyout bid of about $2.6 billion from GlaxoSmithKline (NYSE: GSK), although [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2012/04/biotech-etfs-soar-on-human-genome-bid-gilead-drug-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs Break Out</title>
		<link>http://www.etftrends.com/2012/01/biotech-etfs-break-out/</link>
		<comments>http://www.etftrends.com/2012/01/biotech-etfs-break-out/#comments</comments>
		<pubDate>Thu, 19 Jan 2012 14:45:51 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=74303</guid>
		<description><![CDATA[The rally in biotechnology exchange traded funds is going vertical in early 2012 with the sector&#8217;s largest ETF posting a gain of 20% over the past three months.
The $1.5 billion iShares Nasdaq Biotechnology Index Fund (IBB) is breaking out to new all-time highs. The ETF is up 9.6% year to date, compared with a 4.1% [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2012/01/biotech-etfs-break-out/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Teva, Cephalon Boost Biotech ETFs</title>
		<link>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/#comments</comments>
		<pubDate>Mon, 02 May 2011 15:45:58 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=52575</guid>
		<description><![CDATA[Biotechnology exchange traded funds (ETFs) rallied to open the week after Teva Pharmaceutical (NasdaqGS: TEVA) said it’s buying Cephalon (NasdaqGS: CEPH) for $6.8 billion in a blockbuster sector deal.
The combined company would represent about $7 billion in annual sales. Shares of Teva and Cephalon were both up more than 3% in recent trading.
&#8220;This is transforming [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>April ETF Performance Report</title>
		<link>http://www.etftrends.com/2011/04/april-etf-performance-report-3/</link>
		<comments>http://www.etftrends.com/2011/04/april-etf-performance-report-3/#comments</comments>
		<pubDate>Fri, 29 Apr 2011 22:08:14 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[ETF Performance Reports]]></category>
		<category><![CDATA[DBS]]></category>
		<category><![CDATA[EWG]]></category>
		<category><![CDATA[Silver]]></category>
		<category><![CDATA[SIVR]]></category>
		<category><![CDATA[SLV]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=52477</guid>
		<description><![CDATA[Markets were in full bloom in April, as corporate earnings helped push markets and exchange traded funds (ETFs) higher.  The Dow Jones Industrial Average gained nearly 4% this month and had its highest close since May 2008.  The S&#38;P 500 rose about 3% and the Nasdaq gained 3.5% for the month.
Silver ETFs were the top [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/04/april-etf-performance-report-3/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biogen Earnings, Drug Data to Lift Biotech ETFs</title>
		<link>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/#comments</comments>
		<pubDate>Thu, 21 Apr 2011 12:55:22 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=51598</guid>
		<description><![CDATA[Biogen (NasdaqGS: BIIB) shares jumped more than 20% in premarket action Thursday after the company reported higher-first quarter profit and released encouraging data on an experimental multiple sclerosis drug.
The data on the drug, BG-12, was “very competitive versus other approved and pipeline MS therapies” and the results are “a significant catalyst for Biogen shares,” said [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ETFs And A Global Approach Help Investors Access Biotech</title>
		<link>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/</link>
		<comments>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/#comments</comments>
		<pubDate>Fri, 11 Mar 2011 09:00:37 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=47499</guid>
		<description><![CDATA[Investing in biotech stocks and companies is so much like gambling, the risk is sometimes not worth it. Why not mitigate the risk and invest in an exchange traded fund (ETF) instead, which will give investors exposure to several companies at once.[Dissipate The Risk In Biotechnology With ETFs.]
According to MinyanVille, the process of New Drug [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>5 Biotechnology ETFs to Play Innovation</title>
		<link>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/</link>
		<comments>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/#comments</comments>
		<pubDate>Tue, 22 Feb 2011 22:00:10 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[HOLDRs]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=46796</guid>
		<description><![CDATA[While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector.
Currently, the biotech industry is full of fast-growing and very profitable companies; however, [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ETFs Turn Sunny Side Up on M&amp;A and Earnings</title>
		<link>http://www.etftrends.com/2011/02/etfs-turn-sunny-side-ma-earnings/</link>
		<comments>http://www.etftrends.com/2011/02/etfs-turn-sunny-side-ma-earnings/#comments</comments>
		<pubDate>Wed, 16 Feb 2011 16:30:59 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[Industrial Metals]]></category>
		<category><![CDATA[NASDAQ]]></category>
		<category><![CDATA[PMR]]></category>
		<category><![CDATA[QTEC]]></category>
		<category><![CDATA[Real Estate]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Utilities]]></category>
		<category><![CDATA[VPU]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=46623</guid>
		<description><![CDATA[Reversing a few days of weak starts, exchange traded funds (ETFs) opened higher as investors respond to another round of earnings, corporate deal making and economic reports.

U.S. core producer prices in January rose to their highest rate in more than two years, hinting at a build-up in inflation pressures as the recovery gathers pace, a [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/02/etfs-turn-sunny-side-ma-earnings/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sector ETFs to Play the State of the Union Address</title>
		<link>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/</link>
		<comments>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/#comments</comments>
		<pubDate>Wed, 26 Jan 2011 20:00:06 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Socially Responsible ETFs]]></category>
		<category><![CDATA[Aerospace & Defense]]></category>
		<category><![CDATA[Alternative Energy]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Clean Energy]]></category>
		<category><![CDATA[Energy]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[FXH]]></category>
		<category><![CDATA[GEX]]></category>
		<category><![CDATA[Green ETFs]]></category>
		<category><![CDATA[GRID]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHF]]></category>
		<category><![CDATA[Infrastructure]]></category>
		<category><![CDATA[ITA]]></category>
		<category><![CDATA[IYW]]></category>
		<category><![CDATA[NASI]]></category>
		<category><![CDATA[PBW]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PJP]]></category>
		<category><![CDATA[PPA]]></category>
		<category><![CDATA[QQEW]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>
		<category><![CDATA[XLK]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=45357</guid>
		<description><![CDATA[In his State of the Union address Tuesday, President Barack Obama touched upon the major problems that have crippled our nation and offered an essential directive to invest in our future. If Obama&#8217;s proposals become actualities, something that&#8217;s not necessarily a certainty, then the exchange traded funds (ETFs) below could make moves.
President Obama stressed the [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dissipate the Risk In Biotechnology With ETFs</title>
		<link>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/</link>
		<comments>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/#comments</comments>
		<pubDate>Tue, 18 Jan 2011 22:00:17 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BIB]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[BIS]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=44690</guid>
		<description><![CDATA[The biotechnology sector offers investors the opportunity to bet big and win big, but the potential downside can make a huge dent in your wallet. Perhaps a biotech exchange traded fund (ETF) is more to your liking?
The largest and most liquid broad-based biotech sector iShares Nasdaq Biotechnology (NASDAQ: IBB), which reflects the performance of the [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Play the Booming Biotech Sector With ETFs</title>
		<link>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/</link>
		<comments>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/#comments</comments>
		<pubDate>Tue, 21 Dec 2010 23:00:29 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=43168</guid>
		<description><![CDATA[Economic downturn? What economic downturn? Despite lackluster economic growth, biotechnology exchange traded funds (ETFs) have managed to notch solid performance this year.
In the United Kingdom alone, the bioscience sector has exploded. It now includes 942 companies, with 345 involved in the development, manufacture or sales of therapeutic products, according to PharmaLive. The biotech sector also [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Deal-Making Drives ETFs Higher</title>
		<link>http://www.etftrends.com/2010/12/deal-making-drives-etfs-higher/</link>
		<comments>http://www.etftrends.com/2010/12/deal-making-drives-etfs-higher/#comments</comments>
		<pubDate>Tue, 21 Dec 2010 16:30:43 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Global ETFs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Asia]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Emerging Markets]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[EWP]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IGV]]></category>
		<category><![CDATA[Spain]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>
		<category><![CDATA[XPP]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=43404</guid>
		<description><![CDATA[Exchange traded funds (ETFs) are moving up on Tuesday, lifted by premarket gains for Adobe Systems Inc. after upbeat earnings as well as deal news involving Martek Biosciences Corp. and Chrysler Financial.

Shares of Adobe (NYSE: ADBE) are flying high up over 6% today after the firm posted late Monday fiscal fourth-quarter results that beat Wall [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/12/deal-making-drives-etfs-higher/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

